Apeximmune PLA2G2D Media Package

This media backgrounder provides details on Apex Immune Therapeutics, highlighting their founding, focus on novel immunotherapies, capital raised, pipeline projects, and leadership information.

This article investigates the role of PLA2G2D in tumour-draining lymph nodes and its impact on regulating anti-tumour immune responses.

The document details Apeximmune's discovery of PLA2G2D as a new immune checkpoint target to overcome Anti-PD-1 resistance in cancer, showcasing collaborative research with Erasmus MC revealing promising therapeutic advances.